Rodney Cotton is the newest member of Castle Biosciences’ Board of Directors.
The appointment is effective immediately and will stand for election at Castle’s 2024 Annual Meeting of Stockholders, expected to be held in May 2024. Mara G. Aspinall will not stand for re-election to its board, and her current term will expire at the 2024 Annual Meeting. Ms. Aspinall has served on the Company’s board since 2015.
“Mara has been a great partner and contributor,” says Derek Maetzold, Director, President and Chief Executive Officer of Castle Biosciences, in a news release. “We thank her for her dedicated service to Castle. “Rod’s broad range of leadership experience in the diagnostic industry will be a significant benefit to our board. We are pleased to welcome him.”
With Mr. Cotton’s addition, the Company’s board will be comprised of nine directors, five of whom have been appointed in the past four years.
Mr. Cotton worked at Roche for more than two decades where he served as Senior Vice President, Head of Strategy & Transformation, and Chief of Staff to the CEO for Roche Diagnostics.
While at Roche, Mr. Cotton led milestone corporate communications, health equity coalitions, the U.S./Roche Group audit, and global/U.S. acquisition integrations. During the COVID-19 pandemic, Mr. Cotton and his team at Roche accelerated six products in 11 months, including the first launch of the market’s most accurate and in-demand molecular diagnostic test. He also solved challenges of product scarcity, supply chain, product allocation, and logistics to achieve accelerated global sourcing and self-manufacturing in line with testing guidelines. Mr. Cotton received The Sagamore of the Wabash Award, one of the highest Indiana State honors from Indiana Governor Eric J. Holcomb.
Mr. Cotton currently serves on the board of directors of Eisai Pharmaceutical U.S., a research and development pharmaceutical company and subsidiary of Eisai Company, Ltd., Orchard Software, a private equity-backed health technology company owned by Francisco Partners; an advisory board member to Flo2 Ventures, a venture capital-backed healthcare and health equity accelerator; and serves as a member of the board of directors and on three board committees (Audit, Compliance & Finance; Governance & Equity; and Quality of Care) for Community Health Network.
He holds an MBA from California State University, Dominguez Hills, an MS in strategic management from the University of Southern California, and a BA in biological sciences & technology from the University of California at Santa Barbara.
